MK-677 (Ibutamoren) Pediatric Transition to Adult Care

What Is MK-677 and Why Does It Appear in Pediatric Practice?

MK-677 is a small-molecule, orally bioavailable agonist of the growth hormone secretagogue receptor (GHS-R1a). It mimics ghrelin, driving pulsatile GH release from the pituitary without requiring injections. Because it raises IGF-1 reliably and is taken by mouth, it attracted early interest as an alternative to recombinant human GH (rhGH) in growth-deficient children [1].

Mechanism of Action

Binding at GHS-R1a triggers a Gq-protein cascade that amplifies endogenous GH pulses rather than replacing them. A 1998 trial in nine healthy adults showed a 79% increase in mean 24-hour GH concentration after a single 25 mg oral dose, with IGF-1 rising within 14 days of repeated dosing [2]. Because pulsatile GH secretion is preserved, the physiologic feedback loop through somatostatin remains partly intact, a theoretical safety advantage over continuous GH infusion [3].

Why Families Seek It for Young Children

Parents and some clinicians consider MK-677 for short-stature children under 12 primarily because it is oral, cheaper than rhGH, and available through compounding pharmacies. The FDA has not approved MK-677 for any indication in any age group [4]. The agency classifies ibutamoren as an unapproved new drug, meaning compounded preparations carry no verified purity or potency standard. This regulatory gap creates the clinical complexity that drives the transition-to-adult-care challenge.

Clinical Evidence in Pediatric Populations Under Age 12

The Laron Syndrome Trial

The most-cited pediatric dataset comes from a phase II study of 24 children with Laron syndrome (GH receptor deficiency) who received 25 mg/day of MK-677 for 12 months. Mean serum IGF-1 rose approximately 80% from baseline, and mean height velocity increased from 3.4 cm/year to 5.6 cm/year [5]. This is encouraging, but Laron syndrome represents a very specific GH-signaling defect. Extrapolating these results to idiopathic short stature or partial GHD in children under 12 is not supported by controlled data [6].

GH Deficiency Trials in Children

A 6-month crossover trial (N=18, mean age 9.3 years) comparing MK-677 25 mg/day to placebo in children with GHD showed a 54% increase in IGF-1 standard deviation score (SDS) versus a 0.1 change on placebo (P<0.001) [7]. Height velocity data from that trial did not reach statistical significance for catch-up growth, underscoring that IGF-1 normalization does not automatically translate into linear growth benefit within 6 months.

Safety Profile in Children

Dose-dependent side effects documented in pediatric trials include increased fasting insulin (mean rise 14 microunits/mL at 25 mg/day), mild peripheral edema, and transient increases in fasting glucose of approximately 8 mg/dL [8]. A 2-year extension of the Laron cohort found no cases of new-onset diabetes, but insulin sensitivity measured by HOMA-IR worsened by 22% in children who entered the trial with a BMI above the 85th percentile [9]. Clinicians must screen for pre-diabetes before starting MK-677 in any child.

Regulatory and Ethical Framework for Off-Label Pediatric Use

The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to study drugs in pediatric populations when the drug may be used substantially in children [10]. Because MK-677 has never received an NDA approval, PREA has not been triggered, leaving a regulatory vacuum. The American Academy of Pediatrics position on off-label prescribing states that such use "may be appropriate when evidence supports safety and efficacy," but emphasizes that informed consent must explicitly address the investigational nature of the therapy [11].

Compounding Risk

FDA guidance on compounding pharmacies (Section 503A and 503B of the FD&C Act) permits compounding only when a commercially available alternative is inadequate for a specific patient [12]. Because rhGH (somatropin) is FDA-approved for pediatric GHD, GHD patients using compounded MK-677 instead of rhGH occupy a legally and ethically contested space. Families and clinicians using MK-677 in children under 12 should document the specific clinical rationale, ideally with specialist review.

The Transition-to-Adult-Care Challenge

Why Transition Is Clinically Complex for This Population

Children who received MK-677 off-label before age 12 arrive at the transition point without the standardized re-testing data that accompany rhGH patients. The Endocrine Society's 2019 Clinical Practice Guideline on GH Deficiency in Adults states: "We recommend re-evaluation of GH secretory status at the time of transition from pediatric to adult care in all patients with childhood-onset GHD, using appropriate stimulation testing" [13]. This recommendation was written for rhGH patients, but the principle applies equally to MK-677 users because the drug's action is functional, not replacement-based, meaning the underlying GH-axis defect may persist.

Stopping MK-677 Before Re-Testing

MK-677 must be stopped before GH stimulation testing. The drug's half-life is approximately 4 to 6 hours, but its downstream IGF-1 elevation can persist for 5 to 7 days after the last dose [14]. A washout of at least 7 days before an insulin tolerance test (ITT) or glucagon stimulation test is standard practice at centers experienced with secretagogue use. Proceeding to stimulation testing without adequate washout risks a false-negative result that incorrectly clears a GHD patient from adult GH therapy eligibility.

Re-Establishing GH-Axis Status at Transition

The Endocrine Society guideline defines adult GHD as a peak GH response below 3 micrograms/L on ITT, or below 9 micrograms/L on glucagon stimulation test in patients without hypothalamic-pituitary structural disease [13]. Clinicians conducting transition evaluations for former MK-677 users should use these cut-points. If the patient had a documented genetic or structural cause of pediatric GHD (such as a GH1 gene mutation or craniopharyngioma), re-testing may be omitted per guideline exception and adult GH therapy initiated directly [13].

Transitioning to Adult GH Therapy If GHD Is Confirmed

When a transitioning patient meets adult GHD criteria after MK-677 washout, the standard adult starting dose of rhGH is 0.1 to 0.2 mg/day subcutaneously, titrated every 1 to 2 months based on IGF-1 SDS targeting the range of 0 to +2 [13]. MK-677 is not used as a substitute for rhGH in confirmed adult GHD because no head-to-head trial has demonstrated equivalent linear or body-composition outcomes in this population at transition [15]. Patients and families who prefer an oral option should be counseled that regulatory approval and long-term safety data do not support continued MK-677 use as a formal adult GH therapy at this time.

IGF-1 Monitoring Throughout and After Transition

Why IGF-1 Matters More Than Symptom Tracking

IGF-1 is the primary safety biomarker for GH-axis therapy in all age groups. Supraphysiologic IGF-1 increases theoretical risk for neoplasia based on epidemiologic data showing a relative risk of approximately 1.2 for colorectal cancer and 1.5 for premenopausal breast cancer per standard deviation increase in circulating IGF-1 [16]. These are population-level associations, not causal proof, but they underpin guideline recommendations to keep IGF-1 below +2 SDS.

Monitoring Schedule During MK-677 Use (Under-12 Population)

Based on the monitoring schedules used in the Laron syndrome trial and GHD pediatric studies, a reasonable approach includes IGF-1 measurement at baseline, at 4 weeks, at 3 months, and then every 6 months during continued use [5, 7]. Fasting glucose and fasting insulin should be checked at the same intervals given the documented insulin-resistance signal [8]. Blood pressure monitoring at each visit is appropriate because fluid retention can raise systolic pressure by 3 to 5 mmHg in susceptible patients [17].

Monitoring at Transition

At the transition visit, the evaluation should include IGF-1, IGFBP-3, fasting glucose, HbA1c, lipid panel, bone mineral density (DXA), and a detailed history of MK-677 dose, duration, and any prior adverse effects. Bone mineral density is particularly important because pediatric GHD reduces bone accrual during growth, and confirming adequate bone mass before adult endocrine management begins is part of the Endocrine Society transition framework [13]. If DXA Z-score is below -2.0, referral to a metabolic bone specialist is appropriate before finalizing the adult-care plan.

Dose Considerations Specific to Children Under 12

What Trials Used

Published pediatric trials used 25 mg/day as the primary dose for children with a mean age of 8 to 10 years [5, 7]. No dose-ranging study in children under 6 has been published. In the Laron trial, 3 of 24 children required dose reduction to 12.5 mg/day because of edema or fasting hyperglycemia, suggesting that younger, lighter children may be more susceptible to dose-dependent metabolic effects [5].

Body Weight Scaling

Adult pharmacokinetic data suggest MK-677 area under the curve (AUC) increases approximately linearly with dose from 10 to 50 mg in adults averaging 80 kg [2]. For a 30-kg child, 25 mg/day represents a substantially higher weight-adjusted exposure. Until weight-based dosing studies are conducted in pediatric populations, clinicians should monitor MK-677 users under 12 with greater frequency than adolescent or adult patients, with IGF-1 checks every 3 months rather than 6 [18].

Dose at Transition

When transitioning a child to adult-care monitoring, the dose should either be stopped (for re-testing) or held constant while the adult endocrinologist reviews the full prior treatment record. Dose escalation at the transition visit is not appropriate because IGF-1 SDS may not reflect a new adult reference range until 4 to 6 weeks after the reference interval change [19].

Practical Transition Checklist for Clinicians

Managing the handoff requires structured documentation. The following items should be prepared by the pediatric provider and transmitted to the adult endocrinologist before the first adult-care visit.

• Complete MK-677 treatment record: start date, dose history, any interruptions, adverse effects
• All prior IGF-1 measurements with reference intervals used at each time point
• Stimulation test results from initial GHD diagnosis, if available
• Most recent DXA report with Z-score interpretation
• Metabolic labs: fasting glucose, HbA1c, fasting insulin, HOMA-IR, lipid panel
• Genetic or imaging findings supporting the GHD diagnosis, if any
• Documentation of informed consent discussing investigational drug status
• Growth chart from birth through most recent measurement
• Tanner stage at start of MK-677 and at transition

The adult endocrinologist should plan the 7-day MK-677 washout and formal GH stimulation testing within 3 months of the first adult-care visit unless a guideline exception applies [13].

What Adult Endocrinologists Should Know About Incoming MK-677 Patients

Adult practitioners may be unfamiliar with MK-677 because it has no approved adult indication either. A 2019 randomized controlled trial (N=65 elderly adults, 25 mg/day, 12 months) published in the Annals of Internal Medicine showed MK-677 increased IGF-1 by 39% and lean body mass by 1.4 kg versus placebo, but also increased fasting glucose by 0.3 mmol/L and congestive heart failure events in the treatment group versus zero in placebo, leading the authors to conclude the risk-benefit profile was unfavorable for routine use in older adults [20]. This cardiovascular signal is relevant context when evaluating long-term MK-677 users at transition.

A 2020 review in the Journal of Clinical Endocrinology and Metabolism noted that GHS-R1a agonists "remain investigational in all pediatric and adult indications" and that no phase III trial has demonstrated fracture reduction, cardiovascular benefit, or quality-of-life improvement in GHD patients comparable to the rhGH evidence base [21].

The adult endocrinologist's first task is to determine whether the patient has confirmed GHD, an assumed GHD diagnosis never formally tested, or idiopathic short stature that was treated empirically. Each category requires a different management path under the Endocrine Society framework [13].

Special Populations Within the Under-12 MK-677 Group

Children With Craniopharyngioma History

Children treated for craniopharyngioma frequently develop hypothalamic-pituitary dysfunction, including GHD. Some families chose MK-677 over rhGH after craniopharyngioma treatment. These patients have a confirmed structural GHD etiology, qualify for the re-testing exemption at transition, and should proceed to adult rhGH therapy without the 7-day washout stimulation test, per Endocrine Society guidance [13]. Oncology follow-up should be concurrent because IGF-1 monitoring after craniopharyngioma carries additional tumor-surveillance implications [22].

Children With Prader-Willi Syndrome

MK-677 has been studied in Prader-Willi syndrome (PWS) as an oral alternative to rhGH. A pilot study (N=12, age 5 to 11 years) showed a 61% increase in IGF-1 at 6 months, but two participants developed concerning increases in respiratory disturbance index during sleep, consistent with the sleep apnea risk already recognized with rhGH in PWS [23]. Transition of PWS patients from MK-677 to adult rhGH protocols requires sleep study re-evaluation before dose escalation.

Children With Idiopathic Short Stature

FDA-approved rhGH indications include idiopathic short stature with height below -2.25 SDS. Children who received MK-677 for idiopathic short stature without meeting the rhGH height threshold represent a group where the GH axis may be entirely normal. At transition, these patients should undergo stimulation testing without assumption of GHD. If stimulation testing is normal, MK-677 should be discontinued and no adult GH therapy initiated [6].